Riskpilot← Back to searchSign inGet full accessTissueStory AB
ABActiveOrg 5590107990Sofierovägen 25Web search portal activities · NACE 6391Est. 20150 employees
Revenue 2025
SEK 959K
-51% vs 2024
EBITDA margin
-10.8%
+48% vs 2024
Equity ratio
20.8%
Financial strength
Net profit 2025
SEK 3K
+386% vs 2024
| Revenue | SEK 959K | -51% |
| EBITDA | SEK -103K | +48% |
| Net profit | SEK 3K | +386% |
| Total assets | SEK 1,1M | -34% |
| Equity | SEK 224K | +1% |
| Employees | 0 | — |
Legal name
TissueStory AB
Org number
5590107990
Legal form
Aktiebolag
NACE code
6391 · Web search portal activities
Founded
16 april 2015
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva konsultverksamhet och kompetensutveckling för olika globala processindustrier via internetbaserade plattformar, samt därmed liknande verksamhet.
Address
Sofierovägen 25
Email
hugh@aquaviewab.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 214 | 1 375 | 839 | 1 975 | 959 |
| Staff expenses | — | — | −673 | −1 972 | −967 |
| EBITDA | 457 | 703 | −12 | −199 | −103 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 457 | 703 | −12 | −199 | −103 |
| Net financials | −1 | — | 0 | 20 | 13 |
| Profit before tax | 341 | 544 | 14 | 28 | 3 |
| Tax | −75 | −115 | −11 | −27 | — |
| Net profit | 266 | 429 | 2 | 1 | 3 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 214 | 1 571 | 1 649 | 1 631 | 1 076 |
| Equity | 319 | 488 | 220 | 221 | 224 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 337 | 367 | 737 | 926 | 462 |
| Total debt | 337 | 367 | 737 | 926 | 462 |
EBITDA margin
-10.8%
This company
15.8%
Market median
-168% vs market
20212025
Equity ratio
20.8%
This company
38.2%
Market median
-46% vs market
20212025
Return on equity
1.4%
This company
18.4%
Market median
-92% vs market
20212025
Net profit margin
0.3%
This company
8.1%
Market median
-96% vs market
20212025
Asset turnover
0.89×
This company
1.12×
Market median
+21% vs market
20212025
Debt / equity
3.80×
This company
0.62×
Market median
-513% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HE Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TissueStory AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hugh Edward O'Brian | Chief Executive Officer | 0 companies |
| Lars Göran Peterson | Deputy Board Member | 0 companies |
| Marie Elisabeth Lööb | Deputy Board Member | 0 companies |